

2031, necessary expenses with respect to the research, development, manufacturing, production, and purchase, at the discretion of the Secretary, of vaccines, therapeutics, ancillary supplies necessary for the administration of such vaccines and therapeutics, and medical devices to prevent, prepare for, and respond to SARS-CoV-2 or any viral variant mutating therefrom with pandemic potential and COVID-19 or other public health threats, of which—

“(1) \$4,000,000,000 shall be for the Biomedical Advanced Research and Development Authority to support the research, advanced research, development, manufacturing, and procurement of medical countermeasures, which may include supporting, maintaining, and improving domestic manufacturing surge capacity of medical products or platform technologies for use during a public health emergency, pursuant to section 319L of the Public Health Service Act;

“(2) \$1,500,000,000 shall be for the Strategic National Stockpile pursuant to section 319F-2 of the Public Health Service Act related to the procurement and maintenance of medical products and ancillary medical supplies necessary to respond to public health threats, which may include through the establishment and maintenance of domestic manufacturing surge capacity or vendor managed supply reserves;

“(3) \$2,000,000,000 shall be for the National Institutes of Health to support the research and development of medical countermeasures, including broad-spectrum antivirals for SARS-CoV-2;

“(4) \$1,000,000,000 shall be for the Biomedical Advanced Research and Development Authority to support the research and development of broad-spectrum antivirals for SARS-CoV-2; and

“(5) \$1,500,000,000 shall be for the Secretary for rapid screening, identification, and development of compounds and platform technologies that may support preparedness for and response to a potential public health threat.

**“SEC. 2304. FUNDING FOR COVID-19 VACCINE, THERAPEUTIC, AND DEVICE ACTIVITIES AT THE FOOD AND DRUG ADMINISTRATION.**

“In addition to amounts otherwise available, there is appropriated to the Secretary for fiscal year 2021, out of any money in the Treasury not otherwise appropriated, \$500,000,000, to remain available until expended, to prevent, prepare for, and respond to COVID-19, domestically or internationally, including the development and review of medical countermeasures to address COVID-19 and emerging variants of COVID-19, and which may be used for the evaluation of the continued performance, safety, and effectiveness, including with respect to emerging COVID-19 variants, of vaccines, therapeutics, and diagnostics approved, cleared, licensed, or authorized for use for the treatment, prevention, or diagnosis of COVID-19; facilitation of advanced continuous manufacturing activities related to production of vaccines and related materials; facilitation and conduct of inspections related to the manufacturing of vaccines, therapeutics, and devices delayed or cancelled for reasons related to COVID-19, including modernizing inspection processes; facilitation of the use of real world evidence and real world data for approved, cleared, licensed, or authorized medical products; review of devices authorized for use for the treatment, prevention, or diagnosis of COVID-19; and oversight of the supply chain and mitigation of shortages of vaccines, therapeutics, and devices approved, cleared, licensed, or authorized for use for the treatment, prevention, or diagnosis of COVID-19 by the Food and Drug Administration.

**“SEC. 2305. REDUCED COST-SHARING.**

“(a) IN GENERAL.—Section 1402 of the Patient Protection and Affordable Care Act is amended by redesignating subsection (f) as subsection (g) and by inserting after subsection (e) the following new subsection:

“(f) SPECIAL RULE FOR INDIVIDUALS WHO RECEIVE UNEMPLOYMENT COMPENSATION DURING 2021.—For purposes of this section, in the case of an individual who has received, or has been approved to receive, unemployment compensation for any week beginning during 2021, for the plan year in which such week begins—

“(1) such individual shall be treated as meeting the requirements of subsection (b)(2), and

“(2) for purposes of subsections (c) and (d), there shall not be taken into account any household income of the individual in excess of 133 percent of the poverty line for a family of the size involved.”

“(b) EFFECTIVE DATE.—The amendment made by this section shall apply to plan years beginning after December 31, 2020.

**“Subtitle E—Testing**

**“SEC. 2401. FUNDING FOR COVID-19 TESTING, CONTACT TRACING, AND MITIGATION ACTIVITIES.**

“(a) IN GENERAL.—In addition to amounts otherwise available, there is appropriated to the Secretary of Health and Human Services (in this subtitle referred to as the ‘Secretary’) for fiscal year 2021, out of any money in the Treasury not otherwise appropriated, \$40,080,000,000, to remain available until expended, to”

**SA 1299.** Mr. BURR submitted an amendment intended to be proposed to amendment SA 891 proposed by Mr. SCHUMER (for himself, Mr. WYDEN, Mrs. MURRAY, Mr. BROWN, Mr. PETERS, Mr. CARDIN, Ms. CANTWELL, Ms. STABENOW, Mr. TESTER, Mr. MENENDEZ, Mr. SCHATZ, Mr. CARPER, Mr. LEAHY, and Mr. SANDERS) to the bill H.R. 1319, to provide for reconciliation pursuant to title II of S. Con. Res. 5; which was ordered to lie on the table; as follows:

On page 84, line 9, strike “to be” and all that follows through “COVID-19” on line 19, page 84 and insert the following: to prevent, prepare for, and respond to COVID-19, domestically or internationally, including the development and review of medical countermeasures to address COVID-19 and emerging variants of COVID-19, and which may be used for the evaluation of the continued performance, safety, and effectiveness, including with respect to emerging COVID-19 variants, of vaccines, therapeutics, and diagnostics approved, cleared, licensed, or authorized for use for the treatment, prevention, or diagnosis of COVID-19; facilitation of advanced continuous manufacturing activities related to production of vaccines and related materials; facilitation and conduct of inspections related to the manufacturing of vaccines, therapeutics, and devices delayed or cancelled for reasons related to COVID-19, including modernizing inspection processes; facilitation of the use of real world evidence and real world data for approved, cleared, licensed, or authorized medical products.

**SA 1300.** Mr. BURR submitted an amendment intended to be proposed to amendment SA 891 proposed by Mr. SCHUMER (for himself, Mr. WYDEN, Mrs. MURRAY, Mr. BROWN, Mr. PETERS, Mr. CARDIN, Ms. CANTWELL, Ms. STABENOW, Mr. TESTER, Mr. MENENDEZ, Mr. SCHATZ, Mr. CARPER, Mr. LEAHY, and

Mr. SANDERS) to the bill H.R. 1319, to provide for reconciliation pursuant to title II of S. Con. Res. 5; which was ordered to lie on the table; as follows:

Strike section 2501 and insert the following:

**SEC. 2501. RESEARCH AND DEVELOPMENT OF MEDICAL COUNTERMEASURES AND ANCILLARY MEDICAL SUPPLIES.**

(a) IN GENERAL.—In addition to amounts otherwise available, there is appropriated to the Secretary of Health and Human Services (in this subtitle referred to as the ‘Secretary’) for fiscal year 2021, out of any money in the Treasury not otherwise appropriated, \$7,660,000,000, to remain available through September 30, 2031, necessary expenses with respect to the research, development, manufacturing, production, and purchase, at the discretion of the Secretary, of vaccines, therapeutics, ancillary supplies necessary for the administration of such vaccines and therapeutics, and medical devices to prevent, prepare for, and respond to SARS-CoV-2, or any viral variant mutating therefrom with pandemic potential and COVID-19, or other public health threats, of which—

(1) \$3,064,000,000 shall be for the Biomedical Advanced Research and Development Authority to support the research, advanced research, development, manufacturing, and procurement of medical countermeasures, which may include supporting, maintaining, and improving domestic manufacturing surge capacity of medical products or platform technologies for use during a public health emergency, pursuant to section 319L of the Public Health Service Act (42 U.S.C. 247d-7e);

(2) \$1,149,000,000 shall be for the Strategic National Stockpile pursuant to section 319F-2 of the Public Health Service Act (42 U.S.C. 247d-6b) related to the procurement and maintenance of medical products and ancillary medical supplies necessary to respond to public health threats, which may include through the establishment and maintenance of domestic manufacturing surge capacity or vendor managed supply reserves;

(3) \$1,532,000,000 shall be for the National Institutes of Health to support the research and development of medical countermeasures, including broad-spectrum antivirals for SARS-CoV-2;

(4) \$766,000,000 shall be for the Biomedical Advanced Research and Development Authority to support the research and development of broad-spectrum antiviral drugs for SARS-CoV-2; and

(5) \$1,149,000,000 shall be for the Secretary for rapid screening, identification, and development of compounds and platform technologies that may support preparedness for and response to a potential public health threat.

**SA 1301.** Mr. BURR submitted an amendment intended to be proposed to amendment SA 891 proposed by Mr. SCHUMER (for himself, Mr. WYDEN, Mrs. MURRAY, Mr. BROWN, Mr. PETERS, Mr. CARDIN, Ms. CANTWELL, Ms. STABENOW, Mr. TESTER, Mr. MENENDEZ, Mr. SCHATZ, Mr. CARPER, Mr. LEAHY, and Mr. SANDERS) to the bill H.R. 1319, to provide for reconciliation pursuant to title II of S. Con. Res. 5; which was ordered to lie on the table; as follows:

Strike sections 2402 through 2404 of the amendment and insert the following:

**SEC. 2402. PUBLIC HEALTH SURVEILLANCE AND INFECTIOUS DISEASE FORECASTING.**

In addition to amounts otherwise available, there is appropriated to the Secretary

for fiscal year 2021 out of any money in the Treasury not otherwise appropriated, \$1,750,000,000, to remain available until expended, to support activities related to public health surveillance and disease detection, including for SARS-CoV-2 and any strains of such virus, by providing funding to State, local, Tribal, and territorial public health departments through section 2821 of the Public Health Service Act in order to increase capacity, conduct, expand, and improve activities to sequence genomes, identify mutations, and track the circulation and development of strains of SARS-CoV-2, and to enter into contracts or cooperative agreements with academic institutions and private entities, which may include partnerships with such entities, to support genomic sequencing activities consistent with this subsection, for such activities.

#### SEC. 2403. FUNDING FOR GLOBAL HEALTH.

In addition to amounts otherwise available, there is appropriated to the Secretary for fiscal year 2021, out of any amounts in the Treasury not otherwise appropriated, \$500,000,000, to remain available until expended, for activities to be conducted acting through the Director of the Centers for Disease Control and Prevention to combat SARS-CoV-2, COVID-19, and other emerging infectious disease threats globally, including efforts related to global health security, global disease detection and response, and global immunization, for such activities.

#### SEC. 2404. FUNDING FOR DATA MODERNIZATION AND FORECASTING CENTER.

In addition to amounts otherwise available, there is appropriated to the Secretary for fiscal year 2021, out of any money in the Treasury not otherwise appropriated, \$750,000,000, to remain available until expended, to support the improvement and maintenance of a nationwide public health situational awareness capability pursuant to section 319D(c) of the Public Health Service Act, including the establishment or enhancement of infectious disease data analytics capabilities to facilitate improved infectious disease early warning and forecasting for SARS-CoV-2, its variants, and emerging infectious disease threats that leverages the expertise of academic and private entities, and public health data surveillance and analytics infrastructure modernization initiatives pursuant to section 2823 of the Public Health Service Act, for such activities.

**SA 1302.** Mr. BURR submitted an amendment intended to be proposed to amendment SA 891 proposed by Mr. SCHUMER (for himself, Mr. WYDEN, Mrs. MURRAY, Mr. BROWN, Mr. PETERS, Mr. CARDIN, Ms. CANTWELL, Ms. STABENOW, Mr. TESTER, Mr. MENENDEZ, Mr. SCHATZ, Mr. CARPER, Mr. LEAHY, and Mr. SANDERS) to the bill H.R. 1319, to provide for reconciliation pursuant to title II of S. Con. Res. 5; which was ordered to lie on the table; as follows:

Strike section 2501 of the amendment and insert the following:

#### SEC. 2501. FUNDING FOR PUBLIC HEALTH WORKFORCE.

(a) IN GENERAL.—In addition to amounts otherwise available, there is appropriated to the Secretary of Health and Human Services for fiscal year 2021, out of any money in the Treasury not otherwise appropriated, \$7,660,000,000, to remain available until September 30, 2031, for grants or contracts pursuant to sections 317F, 317G, 765, 766, 767, and 768 of the Public Health Service Act, and for sections 487A and 487B of the Public Health Service Act, related to emerging scientific needs under section 487A(b)(B) and section 487B(b)(B).

(b) TRANSFER OF FUNDS.—Not later than 90 days after the termination of the public health emergency for COVID-19 declared by the Secretary of Health and Human Services on January 31, 2020, any funds remaining unobligated under this section shall transfer to the Fund established under section 319(b) of the Public Health Service Act.

**SA 1303.** Mr. BURR submitted an amendment intended to be proposed to amendment SA 891 proposed by Mr. SCHUMER (for himself, Mr. WYDEN, Mrs. MURRAY, Mr. BROWN, Mr. PETERS, Mr. CARDIN, Ms. CANTWELL, Ms. STABENOW, Mr. TESTER, Mr. MENENDEZ, Mr. SCHATZ, Mr. CARPER, Mr. LEAHY, and Mr. SANDERS) to the bill H.R. 1319, to provide for reconciliation pursuant to title II of S. Con. Res. 5; which was ordered to lie on the table; as follows:

On page 86, line 9, strike “expended” and all that follows through line 20 on page 88 and insert the following:

September 30, 2031, to carry out activities to detect, diagnose, trace, and monitor SARS-CoV-2 and COVID-19 infections and related activities to mitigate the spread of COVID-19.

(b) TRANSFER OF FUNDS.—Not later than 90 days after the termination of the public health emergency declared on January 31, 2020, by the Secretary of Health and Human Services under section 319 of the Public Health Service Act (42 U.S.C. 247d) with respect to COVID-19, any funds remaining unobligated under this section shall transfer to the Fund established under section 319(b) of such Act (42 U.S.C. 247d(b)).

**SA 1304.** Mr. BURR submitted an amendment intended to be proposed to amendment SA 891 proposed by Mr. SCHUMER (for himself, Mr. WYDEN, Mrs. MURRAY, Mr. BROWN, Mr. PETERS, Mr. CARDIN, Ms. CANTWELL, Ms. STABENOW, Mr. TESTER, Mr. MENENDEZ, Mr. SCHATZ, Mr. CARPER, Mr. LEAHY, and Mr. SANDERS) to the bill H.R. 1319, to provide for reconciliation pursuant to title II of S. Con. Res. 5; which was ordered to lie on the table; as follows:

Strike line 1 on page 79 and all that follows through line 12 on page 82 and insert the following:

(b) TRANSFER OF FUNDS.—Not later than 90 days after the termination of the public health emergency for COVID-19 declared by the Secretary of Health and Human Services on January 31, 2020, any funds remaining unobligated under this section shall transfer to the relevant account to support the immunization program authorized pursuant to section 317 of the Public Health Service Act.

**SA 1305.** Mr. SCOTT of South Carolina (for himself and Mr. DAINES) submitted an amendment intended to be proposed to amendment SA 891 proposed by Mr. SCHUMER (for himself, Mr. WYDEN, Mrs. MURRAY, Mr. BROWN, Mr. PETERS, Mr. CARDIN, Ms. CANTWELL, Ms. STABENOW, Mr. TESTER, Mr. MENENDEZ, Mr. SCHATZ, Mr. CARPER, Mr. LEAHY, and Mr. SANDERS) to the bill H.R. 1319, to provide for reconciliation pursuant to title II of S. Con. Res. 5; which was ordered to lie on the table; as follows:

At the end of subtitle G of title IX, insert the following:

#### SEC. 96. DEDUCTION FOR QUALIFIED BUSINESS INCOME MADE PERMANENT.

(a) IN GENERAL.—Section 199A of the Internal Revenue Code of 1986 is amended by striking subsection (i).

(b) EFFECTIVE DATE.—The amendment made by this section shall apply to taxable years beginning after December 31, 2020.

#### SEC. 96. PERMANENT EXTENSION OF LIMITATION ON DEDUCTION FOR STATE AND LOCAL, ETC., TAXES.

(a) IN GENERAL.—Paragraph (6) of section 164(b) of the Internal Revenue Code of 1986 is amended—

(1) by striking “, and before January 1, 2026”, and

(2) by striking “2018 THROUGH 2025” in the heading and inserting “AFTER 2017”.

(b) EFFECTIVE DATE.—The amendments made by this section shall apply to taxable years beginning after December 31, 2020.

**SA 1306.** Ms. LUMMIS submitted an amendment intended to be proposed to amendment SA 891 proposed by Mr. SCHUMER (for himself, Mr. WYDEN, Mrs. MURRAY, Mr. BROWN, Mr. PETERS, Mr. CARDIN, Ms. CANTWELL, Ms. STABENOW, Mr. TESTER, Mr. MENENDEZ, Mr. SCHATZ, Mr. CARPER, Mr. LEAHY, and Mr. SANDERS) to the bill H.R. 1319, to provide for reconciliation pursuant to title II of S. Con. Res. 5; which was ordered to lie on the table; as follows:

At the appropriate place, insert the following:

#### SEC. . LIMITATION ON OBLIGATION OF FUNDS.

No amounts made available under this Act or an amendment made by this Act for a program may be obligated or expended until all amounts made available for the program under the Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 (Public Law 116-123), the Families First Coronavirus Response Act (Public Law 116-127), the Coronavirus Aid, Relief, and Economic Security Act (Public Law 116-136), the Paycheck Protection Program and Health Care Enhancement Act (Public Law 116-139), or division M or N of the Consolidated Appropriations Act, 2021 (Public Law 116-260) are obligated.

**SA 1307.** Ms. LUMMIS submitted an amendment intended to be proposed to amendment SA 891 proposed by Mr. SCHUMER (for himself, Mr. WYDEN, Mrs. MURRAY, Mr. BROWN, Mr. PETERS, Mr. CARDIN, Ms. CANTWELL, Ms. STABENOW, Mr. TESTER, Mr. MENENDEZ, Mr. SCHATZ, Mr. CARPER, Mr. LEAHY, and Mr. SANDERS) to the bill H.R. 1319, to provide for reconciliation pursuant to title II of S. Con. Res. 5; which was ordered to lie on the table; as follows:

At the end of title VIII, add the following:

#### SEC. 8. INCREASED FUNDING FOR VETERANS COMMUNITY CARE PROGRAM.

(a) IN GENERAL.—In addition to amount otherwise made available, there is appropriated to the Secretary of Veterans Affairs for fiscal year 2021, out of any money in the Treasury not otherwise appropriated, \$852,000,000, to remain available until September 30, 2023, for hospital care, medical services, and extended care services furnished under section 1703 of title 38, United States Code.

(b) OFFSET.—Section 2206 shall have no force or effect.

**SA 1308.** Ms. LUMMIS submitted an amendment intended to be proposed to